|Release of report: India Life Sciences Report 2019: Partnering to improve India’s health|
|1130-1230Hrs||Panel discussion I: Being future ready: Tapping into the next wave of pharma growth
The Indian pharma industry has come a long way,evolving from a minor player on the global stage toone of the most prominent drug producersof the world. Today, theindustry not only exports affordable and high-quality generics but also complex intermediates and innovative new drugs. 2019is likely to witnessgrowthof the industry inlocal andinternational markets; however, it will continueto battle challenges like stringent regulatory actions globally, price erosion, tepid drug launches and myopic views on quality.This session aims to discuss some of the key challenges facing the industry today and identify actions needed to ensure it remains on a high-growth trajectory: establishing a Quality Vision and culture, improving export-import competitiveness, discussing the role of contract research and manufacturingplayers and their challenges, and streamlining the regulatory environment to improve ease of doing business (pricing, manufacturing, registration and approvals, investments, etc).
|1230-1330Hrs||Panel discussion II: Indian biopharma: Reforms Boosting Bio-Economy
Biopharmaceuticals including biosimilars and next generation therapies going at genetic and cellular level have become an increasingly important part of the global pharmaceutical industry. On one side when India is moving forward on developing nextgen therapies ensuring access to affordable therapies for chronic diseases, many patents begin to expire and Biosimilars present a huge opportunity for Indian biopharma companies, but they must navigate availability, affordability and acceptability challenges to win in this space. This is akin to the success story in the 2000s where Indian pharmaceutical players responded to the soaring demand for generic drugs and emerged as world leaders in this sector. With recent developments around commercial opportunity becoming more tangible in developed as well as ROW markets, timing is opportune to deliberate on how deeper industry engagement in biosimilars can be triggered in India.
|1430-1530Hrs||Panel Discussion III: Pulse of Public Health-Indian VaccineIndustry: Drivers of Growth
The Indian vaccine industry is a force to reckon with globally, with over 70% of the world’s vaccines coming from India. Indian vaccine players have successfully collaborated in global partnerships to drive technology transfer and innovation. This session focuses on the biggest opportunities for Indian vaccine makers in the next 5 years, challenges facing the industry, methods to facilitate collaboration between industry, academia andgovernment, and key policy shifts needed to enable full potential growth.
|1530-1630Hrs||Panel discussion IV: Can India become The Global Hub for API Manufacturing: How to fulfill ‘Make In India’ Dream
SMEs forman indispensable arm for the growth of pharma industryand contribute upto 30% ofIndia’soverall supply to global markets. India has more than 10000 units manufacturing bulk drugs, intermediates,formulationsincluding specialized players in contract manufacturing. This industry isfacing sustainability challenge like higher cost of utilities, cumbersome land acquisition norms, complex government approvals and growing competition from cheaper imports that compelled to shut down many units. This is not only posing a challenge towards employment, innovative productsand quality of finished products but also health security of the country as many of these APIs are crucial to public health needs. This session aimsto get insights from regulators, policy makers, API industry including contract manufacturersto discuss policyreforms required for the sustainable growth of the sector.
|1645-1745Hrs||Panel discussion V: Digital: Powering the growth of the life sciences industry
Life sciences companies are at an inflection point in their digital evolution –which is no more an optional source of competitive advantage butfastdevelopinginto a must-have. Digital technologies haveanimportant role across the value chain of life sciences companies with the potential to transform R&D, customer reach and engagement, manufacturing, distributionand commercial models. Doctorsand patients, the most important stakeholders for life sciences companies, are also embracing digitalresulting in significant implications for how life sciences companies engage and support them This session aims to discuss the main digital technologies that aretransforming life sciences, get insights on changing doctor practices and how life sciences companies are meeting these evolving doctor needs, get insights from innovative start-ups, understand how life sciences companies can accelerate the adoption of digital, and identify the current regulatory uncertainties and policy changes needed to foster this.
|1745-1845Hrs||Panel discussion VI: Private equity and M&A as a catalyst for growth
Recent years have witnessed a spike in deal activity in the India pharma sector, with >$2B worth of deals recorded in 2018. In addition, strategic M&A especially focused on outbound investments was a dominant theme for Indian life sciences companies. Theseinvestments have driven market consolidation and efficiency, and have also allowed players to develop new enginesof growth by providing access to new products, markets and customers. This session aims to get insights from life sciences leaders on their experience of using PE/M&A to drive growth, understand how PE players view the life sciences investment opportunity, the expected evolution in the coming yearsandregulatory challenges and required policies.